| Identification | Back Directory | [Name]
ICA 069673 | [CAS]
582323-16-8 | [Synonyms]
ICA 069673
ICA069673;ICA-069673
ICA-069673 >=98% (HPLC)
N-(2-Chloro-5-pyrimidinyl)-3,4-difluorobenzamide
Benzamide, N-(2-chloro-5-pyrimidinyl)-3,4-difluoro- | [Molecular Formula]
C11H6ClF2N3O | [MDL Number]
MFCD20926351 | [MOL File]
582323-16-8.mol | [Molecular Weight]
269.63 |
| Chemical Properties | Back Directory | [Boiling point ]
358.9±37.0 °C(Predicted) | [density ]
1.539±0.06 g/cm3(Predicted) | [storage temp. ]
Sealed in dry,Room Temperature | [solubility ]
DNF:30.0(Max Conc. mg/mL);111.26(Max Conc. mM)
DMSO:36.24(Max Conc. mg/mL);134.4(Max Conc. mM)
Ethanol:30.25(Max Conc. mg/mL);112.18(Max Conc. mM) | [form ]
Powder | [pka]
9.47±0.70(Predicted) |
| Hazard Information | Back Directory | [Description]
ICA 069673 is a heteromeric Kv7 channel activator. It is selective for Kv7.2/7.3 over Kv7.3/7.5 (EC50s = 0.69 and 14.3 μM, respectively) and also activates Kv7.4, Kv7.5, and heteromeric Kv7.4/7.5 channels in a dose-dependent manner. ICA 069673 has no activity against hERG, Nav1.5, and Kv7.1 cardiac ion channels (IC50s = >30 μM). Oral administration of ICA 069673 increases latency to first tonic-clonic seizure in the rat maximal electroshock and pentylentetrazol-induced seizure models (ED50s = 1.5 and <1 mg/kg, respectively). Formulations containing ICA 069673 are under clinical investigation for the treatment of epilepsy. | [storage]
Room temperature |
|
|